中文摘要：

目的探讨聚乙二醇干扰素a2a治疗慢性乙型肝炎（CHB）患者血清干扰素浓度和干扰素抗体水平的变化，以及其对疗效的影响。方法41例CHB患者皮下注射聚乙二醇干扰素a2a（派罗欣，罗氏公司）180μg，每周1次，在0、4、12、24和48周时用ELISA法检测干扰素浓度和干扰素抗体水平，并在停药后24周检测干扰素浓度。结果干扰素浓度在0、4、12、24、48周和停药24周时分别为22．9（3．1-45．8）pg／mL、2734（9．2-4224）pg／mL、4025（269-4462）pg／mL、3884（14．5-4567）pg／mL、3978（76．9-5227）pg／mL和62．1（52．3-74．6）pg／mL。干扰素浓度在4、12、24、48周和停药24周与0周相比，差异有统计学意义（t=9．481，P〈0．01；Z=-6．862，P〈0．01；Z=-6．969，P〈0．01；Z=-6．477，P〈0．01；Z=-4．204，P〈0．01）；12、24与4周相比，差异有统计学意义（Z=-4．316，P％0．01；Z=-3．830，P=0．0001）；24周与12周相比，差异无统计学意义（Z=0．367，P=0．7136）。干扰素抗体水平在4、12、24、48与0周相比，差异无统计学意义（Z=1．035，P=0．3007；Z=0．101，P=0．9192；Z=0．158，P=0．8748；Z=1．779，P=0．0752）。结论聚乙二醇干扰素α2a治疗过程中，患者血清干扰素浓度在12周达到稳定浓度，停药24周血清干扰素浓度仍略高于治疗前，而干扰素抗体浓度变化不大，二者无明显相关性。

英文摘要：

Objective To detect serum interferon concentration and interferon antibody levels in chronic hepatitis B patients treated with pegylated interferon and its role in interferon efficacy. Methods Forty-one chronic hepatitis B patients were treated with pegylated interferon a-2a at a dose of 180μg/week. Levels of serum interferon concentration and interfer- on antibody levels were detected by ELISA at weeks 0, 4, 12, 24 and 48, and the levels of serum interferon concentration were detected at 24 weeks off-treatment. Results The levels of serum interferon concentrations were 22. 9（3.1-45.8）pg/mL, 2 734（9.2-4 224）pg/mL, 4 025（269-4 462）pg/mL, 3 884（14.5-4 567）pg/mL, 3 978（76.9-5 227）pg/mL and 62.1 （52.3 74.6）pg/mL at weeks 0, 4, 12, 24, 48 and at 24 weeks off-treatment, respectively. Compared to the level of interferon concentration at week 0, there was statistically significant difference at weeks 4, 12, 24, 48 and at 24 weeks off-treatment （t=9.481, P〈0.01; Z=-6. 862, P〈0.01; Z=-6. 969, P〈0.01; Z=-6.477, P〈0.01; Z=-4. 204, P〈0.01）. Compared to interferon concentration at week 4, there was statistically significant difference of the level at weeks 12 and 24 （Z=-4.316, P〈0.01; Z=-3.830, P=0.000 1）. Compared to serum interferon concentration at week 12, there was no statistically significant difference at week 24（Z = 0. 367, P = 0. 713 6）. Compared to serum level of IFN antibody at week 0, there was no statistically significant difference at weeks 4, 12, 24 and 48（Z =-1. 035, P = 0. 300 7; Z = 0. 101, P = 0. 919 23 Z= 0. 158, P = 0. 874 8; Z = 1. 779, P = 0. 075 2）. Conclusion The level of serum interferon concentration reached a steady concentration at week 12 with pegylated interferon α-2a therapy, and was still a little higher at 24 weeks off-treatment than that at week 0. The level of interferon antibody was not significantly changed at each time point, and it had no correlation with the level of interferon concentration.